Patents by Inventor Xingchun Han

Xingchun Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230248723
    Abstract: The present invention relates to novel therapeutic agents against hepatitis B virus (HBV) infection, particularly inhibitors of viral covalently closed circular DNA (cccDNA) which is the key barrier for HBV cure. Accordingly, the invention provides the pyrrolo[2,3-b]pyrazine compounds of formula (I), as described and defined herein, for use in the treatment of HBV infection. The compounds provided herein are highly potent against HBV infection and enable an improved therapy, particularly of chronic HBV infection and HBV rebound. The present invention further relates to a novel screening assay for the identification of therapeutic agents against HBV infection, particularly cccDNA inhibitors, which is performed in hepatocyte-like cells that recapitulate the complete HBV life cycle following infection with patient-derived HBV.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 10, 2023
    Inventors: Jitao David ZHANG, Xingchun HAN, Song YANG, Miriam TRIYATNI, Brian LEONARD, Angelina WALLIER, Josephine SCHMALER, Daniel TURLEY, Philipp TROPBERGER, Samuel CROSET
  • Publication number: 20230141403
    Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), or pharmaceutically acceptable salts thereof, wherein X, m, n, and R1 to R3 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: December 6, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Xingchun HAN, Christian KRAMER, Holger KUEHNE, Christian LERNER, Mingming LI, Matthias NETTEKOVEN, Theodor STOLL, Min WANG, Song YANG
  • Publication number: 20230133845
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: July 14, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mathis BRAENDLIN, Sandra Marie Joseph GRALL-ULSEMER, Xingchun HAN, Christian LERNER, Mingming LI, Yongqiang LIU, S├ębastien SCHMITT, Jianhua WANG, Yongguang WANG, Min WANG, Song YANG, Chengang ZHOU
  • Publication number: 20230012368
    Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.
    Type: Application
    Filed: June 16, 2021
    Publication date: January 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Baptiste BLANC, Zhanling CHENG, Xingchun HAN, Nawaz KHAN, Christian KRAMER, Holger KUEHNE, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sebastien SCHMITT, Theodor STOLL, Jianhua WANG, Yongguang WANG, Song YANG
  • Publication number: 20220396567
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 28, 2020
    Publication date: December 15, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Song FENG, Xingchun HAN, Chungen LIANG, Kun MIAO, Hong SHEN, Xuefei TAN, Jianping WANG, Li WANG
  • Publication number: 20220396565
    Abstract: Provided are novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 15, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Xingchun HAN, Christian KRAMER, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Jianhua WANG, Lisha WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
  • Patent number: 11447489
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 20, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Xingchun Han, Min Jiang, Yongguang Wang, Song Yang
  • Publication number: 20220096527
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 31, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
  • Patent number: 11225482
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2, A and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: January 18, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Min Jiang, Song Yang
  • Patent number: 11191775
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 7, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun Han, Hassan Javanbakht, Henrik Mueller, Yongguang Wang, Song Yang
  • Patent number: 11168086
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 9, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Xingchun Han, Buyu Kou, Hong Shen, Shixiang Yan, Zhisen Zhang
  • Patent number: 11104674
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R4, A, W, Q and Y are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 31, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Min Jiang, Jianhua Wang, Yongguang Wang, Song Yang
  • Patent number: 10968218
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 6, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Yongguang Wang, Song Yang
  • Publication number: 20210061801
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 21, 2018
    Publication date: March 4, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xingchun HAN, Min JIANG, Yongguang WANG, Song YANG
  • Patent number: 10781206
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R5 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 22, 2020
    Assignee: HOFFMANN LA-ROCHE INC.
    Inventors: Taishan Hu, Hong Shen, Xingchun Han
  • Patent number: 10683299
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: June 16, 2020
    Assignee: HOFFMANN LA ROCHE INC.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Publication number: 20200062748
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Yongguang Wang, Song Yang
  • Publication number: 20190248792
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Publication number: 20190248786
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R5 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Hong Shen, Xingchun Han
  • Publication number: 20190241570
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2, A and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 20, 2018
    Publication date: August 8, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Min Jiang, Song Yang